1 / 63

Indonesia Interferons Market Analysis

This report presents a strategic analysis of the Indonesia Interferons Market and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, main players, growth and demand drivers, challenges & future outlook, etc. This is one of the most comprehensive reports about the Indonesia Interferons Market, and offers unmatched value, accuracy, and expert insights.

Insights10
Download Presentation

Indonesia Interferons Market Analysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Sample Report Indonesia Interferons Market Analysis July 2024

  2. This report presents a strategic analysis of the Indonesia Interferons Market and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, main players, growth and demand drivers, challenges & future outlook, etc. This is one of the most comprehensive reports about the Indonesia Interferons Market, and offers unmatched value, accuracy, and expert insights.

  3. Report Scope Report Attribute Details Number of Pages 70-80 Base Year for Estimation 2023 Forecast Period 2024-2030 Market Overview, Size & Forecasting, Market Segmentation, Growth Factors and Trends, Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement Scenario Report Coverage Quantitative Units Revenue in USD Million/Billion (Mn/Bn) Currency Conversion 1 IDR = 0.000062 USD Research Approach Secondary Research (90%), Primary Research (10%) 3 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  4. Table of Content CONTENT PG. NO. 07-15 1. Market Overview 1.1 Interferons Market Overview 1.2 Interferons Market Overview: Global 1.3 Economic Overview: Indonesia 1.4 Interferons Market Overview: Indonesia 1.5 Healthcare Overview: Indonesia 1.6 Budget of Indonesia Government for Public Insurance 1.7 Top Developments in Indonesia 16-17 2. Epidemiology 2.1 Prevalence 18-23 3. Market Size and Forecasting 3.1 Indonesia Interferons Market Size and Forecasts 3.2 Snapshot of Indonesia Interferons Market Segmentation 4 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  5. Table of Content CONTENT PG. NO. 3.2.1 Market Segmentation: By Type 3.2.2 Market Segmentation: By Application 3.2.3 Market Segmentation: By Distribution Channel 24-28 4. Market Dynamics 4.1 Market Growth Drivers 4.2 Market Growth Restraints 29-36 5. Competitive Landscape 5.1 Key Players in Indonesia Interferons Market 37-42 6. Regulatory and Reimbursement Landscape 6.1 Regulatory Landscape in Indonesia 6.2 Reimbursement Scenario in Indonesia 6.3 Reimbursement Process 5 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  6. Indonesia Interferons Market Analysis 1. Market Overview

  7. 1.1 Interferons Market Overview Interferons are a type of signaling protein. They help the body’s immune system fight infection and other diseases, such as cancer. Interferons are made in the body by white blood cells and other cells, but they can also be made in the laboratory to use as treatments for different diseases ▪ Interferons are the frontline defenders in the body. They initiate signaling cascades by stimulating the infected cells and those nearby to produce cytokines. It is of great importance to the healthcare sector ▪ Advantages of Interferons: Interferons do not develop resistance as quickly as other antiviral medications, such as nucleoside ▪ Interferons have immunomodulatory effects that can enhance the body's natural defense mechanisms against viral infections ▪ They can suppress the growth of new blood vessels (angiogenesis) that feed tumors, thereby inhibiting tumor growth and spread ▪ Illustrative Illustrative

  8. 1.2 Interferons Market Overview: Global (1/2) Top Cancer-types Globally (% market share) 10 Mn Deaths globally due to cancer in 2020 19.3 Mn Cancer cases worldwide in 2020 13% Cancers worldwide are attributed to infections 50% Cancer patients are from Asia Illustrative Illustrative 8 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  9. 1.2 Interferons Market Overview: Global (2/2) Indonesia Market ~$xx Bn Market Illustrative Illustrative 9 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  10. 1.3 Economic Overview: Indonesia Population of Indonesia, (In Bn) GDP Growth of Indonesia, (In %) 2.76 2.74 2.72 2.70 2.67 2.64 5.6% 5.3% 5.1% 5.0% 4.9% 2.62 2.59 3.7% 2.56 5.2% 2.53 5.0% 5.0% -2% 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Population Split (2023) Indonesia’s median age is 30.9 years, which is lower than global median age ▪ By Gender By Age Group Country's population’s global share is 3.3% and it is decreasing at a rate of 1.0% Life expectancy of females is 74.9 years and for males it is 71.1 years Currently 56.4% of the population resides in urban areas Top 3 largest cities are Jakarta, Surabaya, and Bandung ▪ 7% Male 0-14 ▪ 25% Female 15-64 50% 50% ▪ 65+ 68% ▪ Illustrative Illustrative 10 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  11. 1.4 Interferons Market Overview: Indonesia (1/2) 65+ Population in the Indonesia 2012-2021 (In Mn) 70% Cancer patients are diagnosed at late stage 18.6 18.2 17.8 17.2 16.8 11.4% Deaths are caused due to cancer in Indonesia 16.4 16.0 15.7 15.4 15.1 58% Cancer cases occur in people aged 50 years and older $735 Mn Estimated economic cost due to cancer 2012 2013 2014 2015 2016 2017 2018 2019 Illustrative Illustrative 2020 2021 11 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  12. 1.5 Healthcare Overview: Indonesia Public Healthcare Private Healthcare › › Healthcare is decentralized, with funding and service delivery responsibilities shifted to provincial and district governments Indonesia has a large and growing private healthcare sector, with 1,854 private hospitals › Private hospitals in Indonesia generally offer higher-quality care and more specialized services compared to the public system, but at a higher cost › The public healthcare system is organized into a three-tier structure, with Community Health Centers (Puskesmas) at the base providing primary care, followed by Health Sub- Centers and Village-Level Integrated Posts › Private health insurance costs vary greatly depending on the expat's age, medical history, family composition, and desired coverage level › The quality of care at public facilities is variable, with long wait times and limited availability of specialists and equipment › Expats and higher-income Indonesians often opt for private care due to potential limitations in the public system › Indonesia launched the Jaminan Kesehatan Nasional (JKN) national health insurance to achieve universal health coverage Illustrative Illustrative 12 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  13. 1.6 Budget of Indonesia Government for Public Insurance Proposed Budget By Category 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31 Outlays $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633 In Billions Of Dollars Medicare 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7% As % Of GDP National Health Expenditures (NHE) grew 2.7% to $4.3 Tn in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP) ▪ Medicare spending grew 8.4% to $900.8 Bn in 2021, or 21% of total NHE ▪ Private health insurance spending grew 5.8% to $1,211.4 Bn in 2021, or 28% of total NHE ▪ Out of pocket spending grew 10.4% to $433.2 Bn in 2021, or 10% of total NHE ▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 Bn, or 14% of total NHE ▪ Hospital expenditures grew 4.4% to $1,323.9 Bn in 2021, slower than the 6.2% growth in 2020 ▪ Physician and clinical services expenditures grew 5.6% to $864.6 Bn in 2021, slower growth than the 6.6% in 2020 ▪ Prescription drug spending increased 7.8% to $378.0 Bn in 2021, faster than the 3.7% growth in 2020 ▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7% ▪ Illustrative Illustrative 13 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  14. 1.7 Top Developments in Indonesia Latest Deals in Indonesia Company Name Type Year Key Pointers Kalbe Farma, Indonesia's largest pharmaceutical company, launched Serplulimab, an innovative immunotherapy drug for the treatment of lung cancer It is an anti-PD-1 monoclonal antibody that is combined with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) It is the first domestically manufactured lung cancer therapeutic drug in Indonesia ▪ ▪ Drug Launch March, 2024 ▪ Bio Farma has joined a network of vaccine manufacturers backed by the Coalition for Epidemic Preparedness Innovations (CEPI) This collaboration aims to significantly enhance the global capacity to produce vaccines, including those for cancer treatment This partnership will support Bio Farma in establishing a bioprocess laboratory to develop and test new mRNA and viral vector technologies ▪ January, 2024 ▪ Collaboration ▪ Illustrative Illustrative 14 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  15. Indonesia Interferons Market Analysis 2. Epidemiology

  16. 2.1 Prevalence Interferons are a group of signaling proteins produced by the immune system in response to various pathogens, including viruses, bacteria, and tumor cells. They play a crucial role in the body's natural defense mechanisms. There are three main types of interferons: alpha, beta, and gamma ▪ Interferons are typically administered via injection, either subcutaneously or intramuscularly. The frequency of administration can vary from daily to weekly, depending on the specific condition being treated and the type of interferon used ▪ Interferons are particularly effective against viral infections. They work by interfering with viral replication and enhancing the immune system's ability to fight off infections ▪ Some interferons have shown effectiveness in treating certain types of cancer, such as melanoma, leukemia, and Kaposi's sarcoma ▪ Illustrative Illustrative 16 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  17. Indonesia Interferons Market Analysis 3. Market Size and Forecasting

  18. 3.1 Indonesia Interferons Market Size and Forecasts Indonesia Interferons Market Forecast, 2023-2030 2023 2024F 2025F 2026F 2027F 2028F 2029F 2030F 2023 2024 2025 2026 2027 2028 2029 2030 Major Markets Patient ($Mn) 2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12 Indonesia Patient Size ($Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73 % of Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45% Global Market Size ($Bn) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937 Indonesia Market Size ($Bn) 61 74 84 87 91 95 99 106 Illustrative Illustrative 18 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  19. 3.2 Snapshot of Indonesia Interferons Market Segmentation Type Application Distribution Channel Interferon Alpha Hepatitis B Hospital Pharmacies Interferon Beta Hepatitis C Online Pharmacies Interferon Gamma Multiple Sclerosis Retail Phrmacies Melanoma Renal Cell Carcinoma In this section you will get an understanding of the segmentations which will cover the Indonesia Interferons Market ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Illustrative Illustrative 19 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  20. 3.2.1 Market Segmentation: By Type Indonesia Interferons Market Share, By Type (2023) Interferon Gamma Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ ▪ Interferon Alpha ▪ Interferon Beta Illustrative Illustrative 20 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  21. 3.2.2 Market Segmentation: By Application Indonesia Interferons Market Share, By Application (2023) Renal Cell Carcinoma Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Hepatitis B Melanoma ▪ ▪ Multiple Sclerosis Hepatitis C Illustrative Illustrative 21 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  22. 3.2.3 Market Segmentation: By Distribution Channel Indonesia Interferons Market Share, By Distribution Channel (2023) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Retail Pharmacies Hospital Pharmacies ▪ ▪ Online Pharmacies Illustrative Illustrative 22 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  23. Indonesia Interferons Market Analysis 4. Market Dynamics

  24. 4. Snapshot Of Market Growth Drivers And Restraints 4.1.1 Increasing incidences of Immunological disorders by 5% 4.1.2 Favorable regulatory 4.1.3 Increased research and development activities to launch innovative interferon- based medications environment due to the increasing approvals of interferon-beta 4.2.1 High cost of interferon treatments limits access to these therapies 4.2.2 Concerns regarding the long-term side effects associated with interferon treatments Illustrative Illustrative 24 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  25. 4.1 Market Growth Drivers 4.1.1 Increasing Incidences of Immunological Disorders By 5% Boosts Demand For Interferon-Based Treatment Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Prevalence of Hepatitis C In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 2010 2022 2030 Illustrative Illustrative 25 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  26. 4.1 Market Growth Drivers 4.1.2 Favorable Regulatory Environment Due to the Increasing Approvals of Interferon-beta Is Significantly Contributing to Market Expansion Number of new interferon-beta drug approvals over time Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 2010 2022 2030 Illustrative Illustrative 26 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  27. 4.1 Market Growth Drivers 4.1.3 Increased Research and Development Activities to Launch Innovative Interferon-Based Medications Market share of key players in interferon market Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 27 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  28. 4.2 Market Growth Restraints 4.2.1 High Cost of Interferon Treatments Limits Access to These Therapies 4.2.2 Concerns Regarding the Long-Term Side Effects Associated With Interferon Treatments Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ ▪ Our analysis will thoroughly investigate the key restraints that may significantly impact business operations and growth. Illustrative Illustrative 28 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  29. Indonesia Interferons Market Analysis 5. Competitive Landscape

  30. 5.1 Key Players in Indonesia Interferons Market Global Player Here is the list of top 10 companies which will cover in the final report ▪ Local Player 1 6 Each company will have slides for ▪ Roche Kalbe Farma Overview Key details Offerings Name of products Recent activities/ Press Coverage Distribution and Vendor Partners Mergers, Acquisitions and Collaboration Financials If there are specific companies that you would like to be included in the report, please let us know via email In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Illustrative Illustrative o o o o 2 7 Biogen Bio Farma o o o 3 8 Bayer Healthcare Takeda Indonesia o ▪ 4 9 Bristol-Myers Squibb Merck Tbk ▪ 10 5 Novartis Sanbe Farma 30 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  31. 5.1.1 Roche (Continued) Offerings Founded In: 1896 ▪ Roche has a diverse portfolio spanning both pharmaceuticals and diagnostics, allowing it to cater to various medical needs and expand its market presence ▪ Roche employs over 85,000 people worldwide. It sells its products in over 150 countries, including Indonesia. ▪ Roche is recognized for its commitment to quality, innovation, and patient-centricity, enhancing customer trust and loyalty ➢ Pharmaceuticals HQ: Basel, Switzerland ➢ In-vitro Diagnostics Type: Public Revenue: $63.4 Bn (Global) ➢ Point-of-Care Diagnostics Website: www.roche.com ➢ Digital Health Services Recent Activity / Press Coverage ▪ July 05, 2024 — Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness ▪ It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralizing angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) ▪ June 20, 2024 — Roche announced today the launch of the first clinically approved, highly-sensitive in-situ hybridization (ISH) test, the VENTANA® Kappa and Lambda Dual ISH mRNA Probe Cocktail assay ▪ It helps differentiate a B-cell cancer from a normal, reactive immune response, providing diagnostic certainty for healthcare providers and their patients ▪ May 21, 2024 —FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation ▪ It is the 29th Breakthrough Therapy Designation for Roche’s oncology portfolio, a testament to deliver transformative medicines for patients 31 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  32. 5.1.1 Roche (Continued) Latest Deals in Roche Company Name Type Year Key Pointers Roche signed a $30 Mn upfront deal with Remix Therapeutics, a biotech focused on developing small molecules that reprogram RNA processing Through this partnership, Roche gains exclusive rights to develop and commercialize new small molecule therapies using Remix's REMaster drug discovery platform ▪ January, 2024 Partnership ▪ Roche acquired Carmot Therapeutics, a US-based biotech company, for an upfront payment of $2.7 Bn This acquisition allows Roche to expand into the obesity drug market, as Carmot has a pipeline of obesity and metabolic disease treatments It positions Roche as a major player in the GLP-1 agonist space, competing with industry leaders like Novo Nordisk and Eli Lilly ▪ December, 2023 ▪ Acquisition ▪ Illustrative Illustrative 32 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  33. 5.1.1 Roche (Continued) Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F Breakdown of Net Revenue by Segment, 2023 ▪ 1 2 3 4 Illustrative Illustrative 33 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  34. 5.1.1 Company 2 Offerings Founded In: HQ: Type: Revenue: Website: Recent Activity / Press Coverage Illustrative Illustrative 34 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  35. 5.1.1 Company 2 (Continued) Latest Deals in CompanyName Company Name Type Year Key Pointers Illustrative Illustrative 35 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  36. 5.1.1 Company 2 (Continued) Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F Breakdown of Net Revenue by Segment, 2023 ▪ 1 2 3 4 Illustrative Illustrative 36 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  37. Indonesia Interferons Market Analysis 6. Regulatory and Reimbursement Landscape

  38. 6.1 Regulatory Landscape in Indonesia Regulatory Authorities With Jurisdiction Over Drugs, Biologicals, And Medical Devices In Indonesia The Ministry of Health (Kementerian Kesehatan) is the primary governmental body responsible for the health of the people and the overall healthcare system in Indonesia. Its key governmental agencies responsible for the administration of drugs and medical devices are as follows: Indonesian National Agency of Drug and Food Control (Badan Pengawas Obat dan Makanan - BPOM), BPOM is the regulatory authority responsible for overseeing pharmaceuticals, biologicals, medical devices, cosmetics, and food products in Indonesia. ▪ It is also responsible for setting and enforcing quality standards for manufacturing and distribution ▪ Interferons are subject to specific regulations for biologics, which are typically more stringent than those for small-molecule drugs ▪ For imported interferons, there are specific regulations governing the import of pharmaceutical products ▪ Directorate General of Pharmaceutical and Medical Devices (Direktorat Jenderal Kefarmasian dan Alat Kesehatan) under the Ministry of Health is responsible for the registration, evaluation, and control of pharmaceutical and medical device products in Indonesia ▪ Directorate General is responsible for monitoring the safety and quality of pharmaceutical and medical device products even after they have been approved and marketed ▪ Illustrative Illustrative 38 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  39. 6.2 Reimbursement Scenario in Indonesia Regulatory Framework For The Authorization, Pricing, And Reimbursement Of Drugs Key Legislation The key legislation for interferons in Indonesia is the National Drug Policy (Kebijakan Obat Nasional or KONAS) is a comprehensive framework that governs all aspects of pharmaceutical management in Indonesia. It guarantees the safety, efficacy, and quality of drugs in the market and promotes the rational use of medicines Reimbursement Schemes National List of Essential Medicines (NLEM) in Indonesia serves as the primary mechanism to control the prices of unbranded generic drugs, including interferons. Interferons, such as interferon-alpha-2a and interferon-alpha-2b, are likely included in the NLEM as essential medicines for the treatment of conditions like viral hepatitis, certain cancers, and multiple sclerosis. The NLEM is revised every 3-4 years and the latest version from 2013 contains over 500 generic medicines National Drug Formulary (Fornas): It is a complementary list to the NLEM, prepared by the National Committee on the Fornas based on scientific evidence. The Fornas serves as a reference for healthcare insurers, including the National Health Insurance Program (JKN), to determine the list of reimbursable drugs. Interferons are likely included in the Fornas, ensuring their coverage and reimbursement by the major insurance schemes in Indonesia National Health Insurance (JKN): Since 2014, Indonesia has had a national health insurance scheme called JKN (Jaminan Kesehatan Nasional). The scheme covers the costs of essential medicines, including interferons, for the treatment of conditions like viral hepatitis, certain cancers, and multiple sclerosis o o o Illustrative Illustrative 39 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  40. 6.2 Reimbursement Scenario in Indonesia (Continued) Coverage Penetration (% Total Population) Source of Funding Spend on Healthcare (%of Current Health Expenditure) 100% 100% 100% 100% 100% 44.0% Government Expenditure xx 46.0% xx 47.7% xx xx xx 51.0% 51.8% Public Healthcare Coverage Private Health Insurance Out of Pocket 38.9% 37.1% 35.6% 31.5% 32.5% Private Coverage Other NA NA 2019 2020 2021 2022 2023 2017 2018 2019 2020 2021 2022 2023  Public healthcare coverage is provided by the government and includes programs like Medicare and Medicaid  Medicare is a federal program that provides healthcare coverage to individuals who are 65 years of age or older, as well as certain younger people with disabilities 6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy) 14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy) Reimbursement Market Trends ▪ Shift towards value-based care has been a significant trend in Indonesia healthcare system, with payers and providers increasingly focused on improving patient outcomes and reducing costs ▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which incentivize providers to deliver high-quality, cost-effective care Illustrative Illustrative 40 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  41. 6.3 Reimbursement Process The reimbursement process in Indonesia healthcare system can be complex and can vary depending on the type of healthcare service, the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process: Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient ▪ Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the service provided ▪ Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential errors or fraud ▪ Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service provided, based on the negotiated payment rates or fee schedule ▪ Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost of the service, such as deductibles, co-payments, or co-insurance In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 41 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  42. 6.3 Reimbursement Process (Continued) The reimbursement process in Indonesia healthcare system can be complex and can vary depending on the type of healthcare service, the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process: MoH Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient ▪ Market Authorization Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the service provided ▪ Private Payers Public Payers Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential errors or fraud ▪ Health Technology Assessment Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service provided, based on the negotiated payment rates or fee schedule ▪ 1 2 3 Coding Coverage Payment Coding depends on availability code while coverage and payment process decisions are made through an HTA. Illustrative Illustrative 42 A Sample Report on Indonesia Interferons Market Analysis I Confidential

  43. A division of

  44. Life-sciences Market Research Reports you can trust We maintain an extensive database comprising over 30,000 syndicated market research reports within the pharmaceuticals and healthcare sector, offering a global, regional, and country-level perspective. Our services also include the provision of customized research reports, meticulously tailored to align with your specific requirements. www.insights10.com www.insights10.com

  45. Pharma (Diseases & Drugs) Digital Health Market Research Reports across various categories in healthcare OTC & Medical Devices Nutraceuticals At Insights10, our extensive report library spans a diverse range of categories within the field of life sciences. Clinical Trials Healthcare Services Rare Diseases www.insights10.com www.insights10.com

  46. Global Coverage Europe • UK • Germany • France • Italy • Spain • Russia • Netherlands • Sweden • Romania • Switzerland • Poland • Austria • Ireland • Norway • Denmark • Belgium • Portugal • Ukraine • Bulgaria • Finland APAC • India • China • South Korea • Japan • Australia • Indonesia • Hong Kong • New Zealand • Philippines • Singapore • Malaysia • Thailand • Vietnam North America • US • Canada Africa • Egypt • Kenya • South Africa • Algeria • Nigeria • Libya • Tanzania • Morocco Middle East • UAE • Saudi Arabia • Turkey • Lebanon • Kuwait • Qatar Latin America • Brazil • Argentina • Mexico • Ecuador • Venezuela • Senegal Click on the country to see the reports available

  47. What do our reports cover? Market Overview Competitive Landscape 1 6 Growth Drivers & Growth Restraints 2 7 Policy & Regulatory Landscape Epidemiology & Disease type 3 8 Reimbursement Scenario Market Size & Forecast Recent Developments 4 9 Market Segmentation Factors Driving Future Growth 5 10

  48. Our Research Process 01 02 03 04 05 06 Define precise research questions Gather data through secondary research Validate data through primary research interviews Forecast market size and segment analysis Extract key insights from the research findings Compile & present a comprehensive analytical report

  49. Data Triangulation & Data Validation Top Down Approach Find final Examine the total healthcare expenditure in the targeted disease or service domain. market size Assess the proportion of spending allocated to the specific product or treatment category. Predict future market growth or decline based on key market trends & dynamics Predict future market growth or decline based on key market trends & dynamics Analyze product or treatment pricing and reimbursement strategies Find final market size Evaluate consumer or patient demographics and numbers Bottom Up Approach

  50. Report Scope Time Frame Report Attribute Details Quantitative Units Revenue in USD Million/Billion (Mn/Bn) Our pricing and purchase options are adaptable to suit the specific scope of work. Pricing and Purchase Base Year for estimation 2023 Typically, the delivery of the final report falls within a timeframe of 5 to 7 business days, but the exact duration may vary depending on the project's scope. Delivery Timeline Forecast Period 2024- 2030 We are pleased to offer you the option of customizing the report to align with your specific research requirements at no extra charge, provided it falls within the defined scope of the project. Customization

More Related